Understanding Immune Checkpoint Inhibitor Treatment Outcomes in Cancer Survivors
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
This project looks at how immune checkpoint inhibitor treatments work for cancer survivors, especially those of African ancestry, in everyday cancer clinics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11074667 on NIH RePORTER |
What this research studies
Immune checkpoint inhibitors are powerful cancer treatments, but we don't know much about how they affect patients of African ancestry. This project will follow cancer survivors who have received these treatments in community cancer centers. We want to understand if there are differences in how well the treatments work, what side effects occur, and how they impact long-term quality of life for patients of African ancestry compared to those of European ancestry. This will help us learn more about how these important medicines work for everyone.
Who could benefit from this research
Good fit: Ideal candidates are cancer survivors who have received immune checkpoint inhibitor treatment, particularly those of African or European ancestry.
Not a fit: Patients who have not received immune checkpoint inhibitor treatment or do not have advanced cancer may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more personalized and effective cancer care for patients of African ancestry, potentially reducing health disparities.
How similar studies have performed: While immune checkpoint inhibitors have shown broad success, there is limited data specifically on their outcomes and toxicities in patients of African ancestry in community settings, making this a novel focus.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Ambrosone, Christine B. — Roswell Park Cancer Institute Corp
- Study coordinator: Ambrosone, Christine B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.